What is the impact of treatment-sensitive, treatment-dependent, and treatment-resistant cGvHD on clinical outcomes?

Find out here 👉 loom.ly/DsitmhY

#GvHDsm #MedicalEducation

We hope you enjoyed following our live updates and congress coverage from  #EBMT 24 !

Keep an eye on our socials for post-congress key points and insights.

#IME   #cancerresearch   #EBMT

CONGRESS | #EBMT24
Florent Malard, from Sorbonne Université, delivers an interesting presentation on the early access program (EAP) in Europe and reports on clinical outcomes of patients with SR or SD GI acute #GvHD that were treated with pooled allogeneic microbiotherapy MaaT013.

CONGRESS | #EBMT24
Chiara Visintini reviews feedback from a qualitative study evaluating the perception of patients with acute #GvHD about immunosuppressive oral treatment adherence.

The EBMT #TheEBMT #GvHD sm #MedicalCongress

CONGRESS | #EBMT24
Javier Delgado Serrano discusses the impact of delayed administration of ixazomib for the prevention of chronic #GvHD in patients who undergo allo-HSCT.
The EBMT #TheEBMT #GvHD sm #MedicalCongress

CONGRESS | #EBMT24
Attilio Olivieri delivers an interesting presentation on the GITMO prospective study that evaluates the validation of software for chronic #GvHD scoring and response evaluation according to the 2014 NIH consensus criteria.

The EBMT #TheEBMT #GvHD sm

CONGRESS #EBMT24 | Yishan Ye, Zhejiang University School of Medicine discusses an EBMT registry-based analysis of outcomes following allo-HCT using either HAPLO, MSD, or MUD. HAPLO was associated with a higher 2-year NRM. The 180-day CI of grade II-IV aGVHD was higher in

CONGRESS #EBMT24 | Xavier Poiré Cliniques universitaires Saint-Luc discusses old matched sibling donor versus young haplo identical for elderly pts in first remission. HID was associated with lower RI (p=0.01), higher NRM (p=0.01) and higher incidence of grade II-IV aGvHD (p=0.01). #AMLsm #leusm

CONGRESS | #EBMT24 | POSTER
Ingo Muller explores if ruxolitinib and anti-TNFα antibody therapy can improve survival in pediatric patients with severe steroid-refractory #GvHD .
The EBMT #TheEBMT #GvHD sm #MedicalCongress

CONGRESS | #EBMT24 | POSTER
Silke Heidenreich uses safety and efficacy data to conclude that belumosudil, in a real-world setting, is well tolerated and induces favorable responses in patients with chronic #GvHD who have received prior intensive treatment.
The EBMT #TheEBMT

CONGRESS | #EBMT24 | POSTER
Pietro Merli presents data evaluating extended abatacept use with serotherapy to reduce incidences of #GvHD in pediatric patients who received HSCT from HLA-MMUD. Fewer incidences of Grade 2─4 aGvHD were observed in patients who were administered

CONGRESS | #EBMT24 | POSTER
A Samer Al-Homsi provides an update on the ongoing clinical trial assessing the safety and efficacy of adding a short course of abatacept to the PTCy-bortezomib combination.
The EBMT #TheEBMT #GvHDsm #MedicalCongress

CONGRESS | #EBMT24 | POSTER
Xin Liu summarizes that a high frequency of DC3 in CD1c+DC after allo-HSCT is associated with severe #GvHD and emphasizes that frequent examinations of DCs after transplantation are important in predicting GvHD.
The EBMT #TheEBMT #GvHD sm

CONGRESS | #EBMT24 | POSTER
Ying Wang reports data from the phase II study evaluating the safety, efficacy, and PK of oral belumosudil in patients with chronic #GvHD who failed one or more prior lines of systemic therapy. At a median follow-up of 12.9 months, an ORR of 73.3% was

CONGRESS | #EBMT24 | POSTER
Nicolaus Kröger shares data from a retrospective study assessing the use of ruxolitinib monotherapy vs ruxolitinib in combination with ECP for the treatment of patients with steroid-refractory acute #GvHD .
UKE Hamburg The EBMT #TheEBMT #GvHD sm

CONGRESS | #EBMT24 | POSTER
Yuliya Shestovska presents data evaluating the use of novel #GvHD prophylaxis with an intermediate dose of PTCy and abatacept. The incidence of Grade 3─4 aGvHD was 3% in both the standard PTCy dose group and the experimental dose group.
The EBMT #TheEBMT

Congress | #EBMT24 Guillaume Dachy UCLouvain shares a retrospective analysis assessing the impact of fludarabine dose on allo-HSCT with RIC outcomes in older patients with AML in CR1. Lower doses were associated with better LFS and GRFS. #leusm #AMLsm

Congress | #EBMT24 Arnon Nagler Sheba Medical Center highlights results from a retrospective analysis comparing UD-HSCT with PTCy vs no PTCy in patients with AML in CR1. RI, OS, and LFS were similar between the two groups, while GvHD and NRM were lower, and GRFS was higher with PTCy vs

🔔 One hour to go! Don’t miss out on our 30 years of ECP symposium today at #EBMT24 .

Join us live at 16:30–18:00 BST👇

✔ Expert opinions on ECP in #cGvHD
✔ Real patient case study
✔ 1 credit EBAC accreditation

The EBMT Mohamad Mohty Zina Peric Bipin Savani Florent Malard